Role of plasma nitric oxide in complete hydatidiform mole

Purpose of investigation: This prospective study aimed to evaluate any relationship between development of complete hydatidiform mole and plasma levels of nitric oxide (a biologically active mediator derived from L-arginine), and human chorionic gonadotropin beta (beta-hCG; a metabolite involved in trophoblast production).

Methods: Levels of plasma nitric oxide and beta-hCG were measured in 38 patients with complete hydatidiform mole pregnancies, and nitric oxide levels were measured in 31 women with normal pregnancies who formed the control group.

Results: For patients compared with controls, mean plasma concentrations of nitric oxide were significantly higher (35.84 vs 29.54 microM; p < 0.001) and significantly associated with increased risk of hydatidiform mole (odds ratio 1.0105, 95% confidence interval 1.0034-1.0176). No significant relationship was found between plasma levels of nitric oxide and beta-hCG in the patient group.

Conclusion: In patients with complete hydatidiform mole compared with controls, plasma nitric oxide levels were found to be significantly higher and associated with increased molar risk.

hCG; Hydatidiform mole; Nitric oxide

[1] Li H.W., Tsao S.W., Cheung A.N.: "Current understandings of the molecular genetics of gestational trophoblastic diseases". Piacenta, 2002, 23 (1), 20.

[2] Lala P.K., Chakraborty C.: "Role of nitric oxide in carcmogenesis

and tumour progression". Lancet Oncol., 2001, 2 (3), 149

[3] Palmer R.M., Ferrige A.G., Moncada S.: "Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor". Nature, I 987, 327 (6122), 524.

[4] de Belder A.J., Radomski M.W.: "Nitric oxide in the clinical arena". J. Hypertens., 1994, 12 (6), 617.

[5] Brennan P.A., Downie LP., Langdon J.D., Zaki G.A.: "Emergmg role of nitric oxide in cancer". Br. J. Oral Maxillofac. Surg., 1999, 37 (5), 370

[6] Ramsay B., Sooranna S.R., Johnson M.R.: "Nitric oxide synthase activites in human myometrium and villous trophoblast throughout pregnancy". Obstet. Gynecol., 1996, 87 (2), 249.

[7] Ariel I., Hochberg A., Shochina M.: "Endothelial nitric oxide synthase immunoreactivity in early gestation and in trophoblastic disease". J. Clin. Pathol., 1998, 51 (6), 427.

[8] Sanyal M., Nag T.C., Das C.: "Localization of nitric oxide synthase in human trophoblast cells: role of nitric oxide in trophoblast proliferation and differentiation". Am. J. Reprod. Immunol., 2000, 43 (2), 70.

[9] Myat T., Hitsumoto Y., Saheki S., Kitagawa H., Yano J., Matsuura S.: "Attenuation of human chorionic gonadotropin release by nitric oxide in choriocarcinoma cell lines". J. Endocrinol., 1996, 150 (2), 243,

[10] Freedman R.S., Tortolero-Luna G., Pandey D.K., Malpica A., Baker V.V., Whittaker L. et al.: "Gestational Trophoblastic Disease". Obstet. Gynecol. Clin. North Am., 1996, 23 (2), 545.

[11] Menczer J., Modan M., Serr D.M.: "Prospective follow-up of patients with hydatidiform mole". Obstet. Gynecol., 1980, 55 (3), 346.

[12] Genest D.R., Laborde 0., Berkowitz R.S., Goldstein D.P., Bernstein M.R., Lage J.: "A clinicopathologic study of 153 cases of complete hydatidiform mole (1980-1990): histologic grade lacks prognostic significance". Obstet. Gynecol., 1991, 78 (3 Pt 1), 402.

[13] Thomsen L.L., Lawton F.G., Knowles R.G., Beesley J.E., RiverosMoreno V., Moncada S.: "Nitric oxide synthase activity in human gynecological cancer". Cancer Res., 1994, 54 (5), 1352.

[14] Thomsen L.L., Miles D.W., Happerfield L., Bobrow L.G., Knowles R.G., Moncada S.: "Nitric oxide synthase activity in human breast cancer". Br. J. Cancer, 1995, 72 (1), 41.

[15] Moriyama A., Masumoto A., Nanri H., Tabaru A., Unoki H., Imoto I. et al.: "High plasma concentrations of nitrite/nitrate in patients with hepatocellular carcinoma". Am. J. Gastroenterol., 1997, 92 (9), 1520.